03-Appendix_A-2019-07-16-American_Epilepsy_Society-FDA_Comments-CBD.pdf (313.71 kB)
Supplemental Material, 03-Appendix_A-2019-07-16-American_Epilepsy_Society-FDA_Comments-CBD - American Epilepsy Society (AES): Written Comments to Norman E. “Ned” Sharpless, MD, Acting Commissioner of Food and Drugs, U.S. Food and Drug Administration (FDA), Department of Health and Human Services (HHS): on Docket ID# FDA-2019-N-1482, Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds; Public Hearing; Request for Comments: Submitted on: July 16, 2019
Version 2 2019-11-04, 17:06
Version 1 2019-10-24, 12:07
journal contribution
posted on 2019-11-04, 17:06 authored by Timothy E. Welty, Kevin E. Chapman, R. Edward Faught, Robert J. KotloskiSupplemental Material, 03-Appendix_A-2019-07-16-American_Epilepsy_Society-FDA_Comments-CBD for American Epilepsy Society (AES): Written Comments to Norman E. “Ned” Sharpless, MD, Acting Commissioner of Food and Drugs, U.S. Food and Drug Administration (FDA), Department of Health and Human Services (HHS): on Docket ID# FDA-2019-N-1482, Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds; Public Hearing; Request for Comments: Submitted on: July 16, 2019 by Timothy E. Welty, Kevin E. Chapman, R. Edward Faught and Robert J. Kotloski in Epilepsy Currents